• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

评估自体和异体细胞在再生医学中的价值。

Assessing the value of autologous and allogeneic cells for regenerative medicine.

机构信息

Advanced Centre for Biochemical Engineering, University College London, London, UK.

出版信息

Regen Med. 2009 Nov;4(6):835-53. doi: 10.2217/rme.09.64.

DOI:10.2217/rme.09.64
PMID:19903003
Abstract

The advantages and disadvantages of autologous and allogeneic human cells for regenerative medicine are summarized. The comparison of relative advantages includes: ease and cost of treating large numbers of patients, the speed of availability of therapy and the differing complexity of the development pathways. The comparison of relative disadvantages deals with issues such as variability of source material, the risks of cell abnormality and of viral and prion contamination, and the sensitive issues surrounding use of embryo-derived cells. From the comparisons, several potentially decisive issues are drawn out, such as possible immune response and teratoma formation, the impact of patents and the virtues of hospital versus industry-centered development.

摘要

总结了用于再生医学的自体和同种异体人类细胞的优缺点。相对优势的比较包括:治疗大量患者的难易程度和成本、治疗方法的可用性速度以及开发途径的复杂程度不同。相对劣势的比较涉及到诸如来源材料的可变性、细胞异常和病毒及朊病毒污染的风险以及围绕胚胎来源细胞使用的敏感问题等问题。通过比较,得出了几个潜在的决定性问题,例如可能的免疫反应和畸胎瘤形成、专利的影响以及医院与工业为中心的发展的优点。

相似文献

1
Assessing the value of autologous and allogeneic cells for regenerative medicine.评估自体和异体细胞在再生医学中的价值。
Regen Med. 2009 Nov;4(6):835-53. doi: 10.2217/rme.09.64.
2
Autologous stem cells for personalised medicine.自体干细胞用于个性化医疗。
N Biotechnol. 2012 Sep 15;29(6):641-50. doi: 10.1016/j.nbt.2012.04.002. Epub 2012 Apr 27.
3
Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.造血干细胞移植操作作为一种免疫治疗机制。
Int Immunopharmacol. 2003 Aug;3(8):1121-43. doi: 10.1016/S1567-5769(03)00014-6.
4
Cell therapy for cardiovascular disorders: coming of age?心血管疾病的细胞治疗:走向成熟了吗?
Artif Organs. 2006 Apr;30(4):211-2. doi: 10.1111/j.1525-1594.2006.00208.x.
5
Endothelial-like vascular progenitor cells (VPCs) from allogeneic and autologous donors: mobilization features distinct from hematopoietic progenitors.来自异体和自体供体的内皮样血管祖细胞(VPCs):动员特征与造血祖细胞不同。
Biol Blood Marrow Transplant. 2007 Apr;13(4):433-9. doi: 10.1016/j.bbmt.2006.11.016. Epub 2007 Feb 15.
6
Amniotic fluid-derived stem cells in regenerative medicine research.羊膜衍生干细胞在再生医学研究中的应用。
Arch Pharm Res. 2012 Feb;35(2):271-80. doi: 10.1007/s12272-012-0207-7. Epub 2012 Feb 28.
7
Anti-HLA antibodies in regenerative medicine stem cell therapy.再生医学干细胞治疗中的抗 HLA 抗体。
Hum Immunol. 2012 Dec;73(12):1287-94. doi: 10.1016/j.humimm.2012.06.010. Epub 2012 Jul 10.
8
Editorial: Alloimmune Response From Regenerative Medicine.社论:再生医学中的同种免疫反应
Front Immunol. 2019 Jan 18;9:3121. doi: 10.3389/fimmu.2018.03121. eCollection 2018.
9
[Current regenerative therapy for the cornea].[当前的角膜再生疗法]
Nihon Rinsho. 2008 May;66(5):955-60.
10
Assessing commercial opportunities for autologous and allogeneic cell-based products.评估自体和同种异体基于细胞的产品的商业机会。
Regen Med. 2012 Sep;7(5):721-32. doi: 10.2217/rme.12.40.

引用本文的文献

1
Expectations regarding regenerative medicine and attitudes toward invasive surgical therapies in patients with Parkinson's disease: A cross-sectional survey.帕金森病患者对再生医学的期望及对侵入性手术治疗的态度:一项横断面调查。
Clin Park Relat Disord. 2025 May 6;12:100341. doi: 10.1016/j.prdoa.2025.100341. eCollection 2025.
2
Challenges and opportunities in the compassionate use of out-of-specification products in autologous regenerative medicine.自体再生医学中不合格产品同情用药的挑战与机遇
Stem Cell Res Ther. 2025 May 13;16(1):238. doi: 10.1186/s13287-025-04343-0.
3
Induced pluripotent stem-cell-derived corneal epithelium for transplant surgery: a single-arm, open-label, first-in-human interventional study in Japan.
诱导多能干细胞来源的角膜上皮用于移植手术:日本一项单臂、开放标签、首次人体介入研究。
Lancet. 2024 Nov 16;404(10466):1929-1939. doi: 10.1016/S0140-6736(24)01764-1. Epub 2024 Nov 7.
4
Bone marrow-derived mesenchymal stem cells reduce CCl-induced kidney injury and fibrosis in male Wistar rats.骨髓间充质干细胞可减轻雄性 Wistar 大鼠 CCl4 诱导的肾损伤和纤维化。
Ren Fail. 2024 Dec;46(2):2319330. doi: 10.1080/0886022X.2024.2319330. Epub 2024 Jul 25.
5
A systematic review and meta-analysis of clinical trials assessing safety and efficacy of human extracellular vesicle-based therapy.一项系统评价和荟萃分析临床试验评估基于人细胞外囊泡治疗的安全性和有效性。
J Extracell Vesicles. 2024 Jul;13(7):e12458. doi: 10.1002/jev2.12458.
6
Hyperbaric oxygen therapy: future prospects in regenerative therapy and anti-aging.高压氧疗法:再生治疗与抗衰老的未来前景
Front Aging. 2024 May 2;5:1368982. doi: 10.3389/fragi.2024.1368982. eCollection 2024.
7
Comparative effect of platelet- and mesenchymal stromal cell-derived extracellular vesicles on human cartilage explants using an ex vivo inflammatory osteoarthritis model.使用体外炎症性骨关节炎模型比较血小板和间充质基质细胞衍生的细胞外囊泡对人软骨外植体的作用。
Bone Joint Res. 2023 Oct 19;12(10):667-676. doi: 10.1302/2046-3758.1210.BJR-2023-0109.R1.
8
Gene therapy approaches for equine osteoarthritis.马骨关节炎的基因治疗方法。
Front Vet Sci. 2022 Sep 28;9:962898. doi: 10.3389/fvets.2022.962898. eCollection 2022.
9
Clinical Trials Using Mesenchymal Stem Cells for Spinal Cord Injury: Challenges in Generating Evidence.临床应用间充质干细胞治疗脊髓损伤的试验研究:证据生成的挑战
Cells. 2022 Mar 17;11(6):1019. doi: 10.3390/cells11061019.
10
Cell Therapy for Neurological Disorders: The Perspective of Promising Cells.用于神经疾病的细胞疗法:有前景的细胞的视角
Biology (Basel). 2021 Nov 6;10(11):1142. doi: 10.3390/biology10111142.